# Shasqi

Source: https://onco.cc/companies/shasqi/  
OnCo record `shasqi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shasqi puts an inert form of a chemotherapy drug into the bloodstream and switches it on only inside the tumour, using a chemical reaction called click chemistry, so the rest of the body sees far less of the drug.

## Summary

Shasqi's CAPAC platform (Click Activated Protodrugs Against Cancer) localises a tetrazine-modified biopolymer at the tumour, then infuses a trans-cyclooctene-caged protodrug that is activated by an in vivo click reaction where the two meet. The lead programme SQ3370 delivers a doxorubicin protodrug and completed a first-in-human phase 1 study in advanced solid tumours including soft tissue sarcoma, reporting that the approach allowed doxorubicin exposures well above conventional dosing with manageable toxicity. The company has raised venture rounds since YC and continues clinical development; amounts are not recorded here because no primary source was fetched.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.shasqi.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/shasqi
- Official website: https://www.shasqi.com

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/shasqi.json